Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from USFDA

Alembic Pharma partner NATCO gets USFDA tentative nod for generic Olaparib tablets; US market size at USD 1.4 bn

Alembic Pharmaceuticals and NATCO Pharma received tentative USFDA approval for generic Olaparib tablets. This approval is for a cancer drug, which is a generic equivalent of Lynparza. Alembic will distribute the product while NATCO Pharma will manufacture the tablets. The product addresses a significant market opportunity, estimated at USD 1.4…

The Economic Times

Alembic Pharma gets USFDA nod for generic influenza treatment drug

Alembic Pharmaceuticals has secured USFDA approval for its generic oseltamivir phosphate oral suspension, a key treatment for influenza. This development offers a more accessible option for patients aged two weeks and above suffering from acute, uncomplicated flu. The approval marks a significant step in providing affordable alternatives to the reference…

The Economic Times

Alembic Pharma gets tentative nod from USFDA for generic cancer drug

Alembic Pharmaceuticals has secured tentative approval from the USFDA for its generic Binimetinib tablets. This marks a significant step for the company in the cancer treatment drug market. The approval is for the 45mg strength, with potential for marketing exclusivity. Alembic previously received tentative approval for the 15mg strength. Binimetinib…

The Economic Times

From analysis to the latest developments in health,
read the most diverse news in one place.

USFDA concludes inspection at Jubilant HollisterStier's Spokane plant with 8 observations

Jubilant Pharmova announced its US subsidiary, Jubilant HollisterStier LLC, underwent a USFDA inspection. The facility in Spokane, Washington, received eight observations. These observations do not involve sterility assurance concerns. The company will submit its response to the US health regulator within 15 business days. Jubilant Pharmova is committed to addressing…

The Economic Times

HPV vaccine rollout faces wild theories and real questions. The govt is unready for both

The recent launch of a nationwide vaccination programme aimed at preventing cervical cancer in teenage girls and women has been met with scepticism and doomsday predictions by a section of very vocal critics of vaccination on social media.

Newslaundry

7 Things That Will Get Cheaper After Budget 2026

Most budgets promise relief. Very few actually change what you pay in real life. Budget 2026 is one of those rare ones that works quietly. There were no dramatic tax cuts, no loud announcements, and no instant price drops flashed across screens. Yet, beneath the fine print, the government made…

Times Life

Further cat food recalled amid bird flu concerns with more cats falling ill

The US Food and Drug Administration has recalled a further four products

PetsRadar

Read news from The Economist, FT, and more,
with one subscription

Non-nutritive sweeteners: A safe tool to reduce sugar, calories among different consumer age groups

Non-nutritive sweeteners (NNS), also known as low and no-calorie sweeteners (LNCS), are alternatives that contain zero or very low amounts of carbohydrates or energy. These sweeteners can act as an effective tool to reduce caloric content and sugar, which when consumed in excess and without proper diet or exercise, can…

The Times of India

Realty developer Aparna Group forays into pharmaceuticals business

The United States Food and Drug Administration had audited the facility in September 2023.

The Hindu

India, U.S. discuss ways to boost trade, investments ties at TPF meet

New Delhi and the U.S. discuss trade and investment ties, addressing issues such as social security and market access.

The Hindu

Leader of the most comprehensive non-surgical laser hair transplantation centre

“The centre of the most exclusive technique to increase the thickness and number of hairs without surgery. The Comprehensive solutions to all hair loss and thinning hair in one place”

Bangkok Post

India must act on drug adulteration – lives around the world are at stake

Cases of disregard for manufacturing standards are risking the country’s reputation as the ‘developing world’s pharmacy’

The Guardian - UK

Zenara Pharma gets CDSCO nod to make copy of Pfizer’s Paxlovid

Combi pack of Nirmatrelvir, Ritonavir tablets is for patients with moderate symptoms of Covid-19

The Hindu

Hyderabad-based Zenara Pharma gets CDSCO nod to manufacture generic version of Pfizer's Covid-19 pill

HYDERABAD: Hyderabad-based Zenara Pharma, a fully-owned subsidiary of Biophore India Pharmaceuticals, on Thursday said it has received emergency use authorisation (EUA) from the Central Drugs Standard Control Organization (CDSCO) to manufacture and market in India a generic version of Pfizer’s Covid-19 pill Paxlovid for the treatment of patients with mild…

The Times of India

Get all your
news in one place.

100's of premium titles.
One news app.

The Times of India

US Food and Drug Administration lifts clinical hold, Covaxin trials to resume

HYDERABAD: The US Food and Drug Administration (USFDA) has lifted the clinical hold on the Phase 2 and 3 immuno-bridging clinical trials of Bharat Biotech’s Covid-19 vaccine, Covaxin, in the US.

The Hindu

Morning Digest | Four militants behind J&K targeted killings shot dead; Covaxin trials in U.S. put on hold, and more

A select list of stories to read before you start your day

Newslaundry

The Bedaquiline Question

One of the increasingly contentious public health issues in India is the manner in which clinical trials are conducted for new drugs and the manner in which these new drugs are subsequently approved for use on Indian patients.

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Bharatiya Janata Party

Food and Drug Administration

the US Food and Drug Administration

71 stories

US Food and Drug Administration

63 stories

Bharat Biotech

53 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.